Tetraspanin 7 autoantibodies predict progressive decline of beta cell function in individuals with LADA

Aims/hypothesis The aim of this work was to investigate whether tetraspanin 7 autoantibodies (TSPAN7A) are valuable in predicting poor beta cell function in individuals with latent autoimmune diabetes in adults (LADA). Methods The cross-sectional study involved participants with LADA ( n  = 173), ty...

Full description

Saved in:
Bibliographic Details
Published in:Diabetologia 2019-03, Vol.62 (3), p.399-407
Main Authors: Shi, Xiajie, Huang, Gan, Wang, Yanfei, Liu, Zhenqi, Deng, Chao, Li, Xia, Zheng, Peilin, Zhou, Zhiguang
Format: Article
Language:English
Subjects:
Adolescent
Adult
Autoantibodies
Autoantibodies - immunology
Autoimmune diseases
Beta cells
Diabetes
Diabetes mellitus
Diabetes mellitus (insulin dependent)
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 1 - immunology
Diabetes Mellitus, Type 2 - immunology
Disease Progression
Female
Glutamate decarboxylase
Human Physiology
Humans
Immunoprecipitation
Insulin-Secreting Cells - immunology
Internal Medicine
Latent Autoimmune Diabetes in Adults - immunology
Male
Medicine
Medicine & Public Health
Metabolic Diseases
Middle Aged
Nerve Tissue Proteins - immunology
Peptides
Prospective Studies
Risk factors
Tetraspanins - immunology
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims/hypothesis The aim of this work was to investigate whether tetraspanin 7 autoantibodies (TSPAN7A) are valuable in predicting poor beta cell function in individuals with latent autoimmune diabetes in adults (LADA). Methods The cross-sectional study involved participants with LADA ( n  = 173), type 1 diabetes ( n  = 158), type 2 diabetes ( n  = 204) and healthy control participants ( n  = 170). The longitudinal study involved 53 participants with LADA, with a 3-year follow-up. In both cohorts, TSPAN7A in the sera were measured by a luciferase immunoprecipitation system assay, and physical and clinical characteristics were recorded. Results The prevalence of TSPAN7A in LADA, type 1 diabetes, type 2 diabetes and healthy control participants was 21.4% (37/173), 26% (41/158), 0.5% (1/204) and 1.2% (2/170), respectively. Importantly, measurement of TSPAN7A significantly increased the number of individuals with LADA found to be positive for multiple antibodies (32.4% vs 22%; p  
ISSN:0012-186X
1432-0428
DOI:10.1007/s00125-018-4799-4